Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

The Prostate

Prostate cancer complications

What is the PCA3 Test?

Prostate Cancer Treatment

The International Prostate Symptoms Score (IPSS)

What is benign prostatic hyperplasia?

Palliative treatment and end of life care for prostate cancer

Choosing the best treatment of prostate cancer - by stage

Prostate Cancer Risk Factors

Prostate Cancer Research

Prostate Cancer Questions

See more featured articles »

Single Nucleotide Polymorphisms and Prostate Cancer

Prostate Cancer Staging

What is Prostatitis?

Prostate Cancer Diagnosis

Recent Genetic Breakthroughs in Prostate Cancer Research

Prostate Cancer and Diet

Life after prostate cancer treatment

Prostate Cancer Partin Tables

Brachytherapy for Prostate Cancer

Breakthroughs in Prostate Cancer Treatments

Prostate Cancer Epidemiology Worldwide

What is the Gleason Score?

What Should You Avoid Before a PSA Test?

Causes of prostatitis

Radiation therapy for prostate cancer

Cryosurgery for prostate cancer

Survival rates of prostate cancer

Precancerous conditions of the prostate

Rectal Examination for Prostate Cancer

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Should MRI be Used to Diagnose Prostate Cancer?

What is the PSA Test?

Prostate Cancer Epidemiology

Prostate Cancer Screening

What is Prostatectomy?

Diagnosis of prostatitis

Hormonal therapy for prostate cancer

Prostate Cancer Symptoms

Prostate Cancer and Genetics

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Can Curcumin Prevent or Treat Prostate Cancer?

Treatment of prostatitis

Prostatitis symptoms

Symptoms of Benign Prostatic Hyperplasia (BHP)

Prostate cancer alternative and complementary therapies

Types of PSA Test

Prostate Cancer Cell Dormancy and Activation

What is TURP?

Treatment of Benign Prostatic Hyperplasia (BHP)

PSA Test in Men Who Have Been Treated for Prostate Cancer

PSA False Positive and False Negative Results

Prostate Biopsy

Differentiating between prostate cancer and prostate enlargement

Gold Nanoparticles Use in Prostate Cancer

Causes of benign prostatic hyperplasia

Prostate cancer prevention

Vasectomy and prostate cancer: Myth or reality?

Prostate Cancer and Exercise

What is medical castration?

Latest Prostate Cancer News and Research

New imaging technique boosts survival in prostate cancer patients

A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph's Health Care London (Lawson), and University Health Network (UHN) has found a novel imaging solution, called prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scanning, can more effectively detect the recurrence of prostate cancer compared to standard imaging methods, and is associated with improved survival outcomes.

14 Oct 2025

Why brittle bones aren’t just a woman’s problem

Ronald Klein was biking around his neighborhood in North Wales, Pennsylvania, in 2006 and tried to jump a curb. "But I was going too slow — I didn't have enough momentum," he recalled.

14 Oct 2025

Blocking two enzymes weakens prostate tumors and boosts drug effectiveness

A major international study has uncovered a new vulnerability in prostate cancer cells that could help improve treatment for one of the most common cancers affecting men.

13 Oct 2025

Innovative screening tool launched to identify individuals at risk for hereditary cancers

Ochsner Health announces the launch of its Genetic Wellness Assessment, an innovative screening tool to help identify individuals at risk for hereditary cancers.

9 Oct 2025

Many men receive frequent prostate cancer tests without symptoms

Current prostate specific antigen (PSA) testing "may not effectively target testing to those most likely to benefit, raising concerns about overtesting" warn researchers from the University of Oxford in a study of over 10 million men across England published by The BMJ today.

8 Oct 2025

Housing support programs tied to improved cancer detection among seniors

A new study led by researchers from the Johns Hopkins Bloomberg School of Public Health found that older adults receiving federal housing assistance were on average diagnosed at earlier stages with three common cancers-colon, breast, and non-small cell lung-compared to peer cancer patients who were not receiving assistance.

8 Oct 2025

Scientists develop a high accuracy blood test to diagnose Chronic Fatigue Syndrome

Scientists at the University of East Anglia and Oxford Biodynamics have developed a high accuracy blood test to diagnose Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (ME/CFS).

7 Oct 2025

Unlocking the mysteries of treatment-resistant prostate cancer

Advances in prostate cancer early detection and treatment have improved outcomes in men diagnosed with the disease.

7 Oct 2025

New drug combination could delay the progression of advanced prostate cancer

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL researchers.

7 Oct 2025

NCCN enhances widely used breast cancer guidelines with advanced digital features

Today, the National Comprehensive Cancer Network® (NCCN®)-a nonprofit responsible for globally utilized guidelines for cancer care-is sharing new NCCN Guidelines Navigator™ resources for breast cancer treatment as well as genetic/familial high-risk assessment, during Breast Cancer Awareness Month.

7 Oct 2025

New ASPIRE trial tests chemotherapy combination for advanced prostate cancer

The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial-a large-scale, Phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend survival for men living with advanced prostate cancer.

6 Oct 2025

Nuclear missile workers are contracting cancer. They blame the bases.

At a memorial service in 2022, veteran Air Force Capt. Monte Watts bumped into a fellow former Minuteman III nuclear missile operator, who told him that she had non-Hodgkin lymphoma.

3 Oct 2025

Engineered CAR T cells show promise against solid tumors

Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers.

2 Oct 2025

Genetic risk scores fail to predict survival after diagnosis

Research indicates that disease susceptibility genetics poorly predict survival, while longevity PGSs offer stronger associations with post-diagnosis mortality.

2 Oct 2025

Five-session SBRT reduces side effects in intermediate-risk prostate cancer

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to results of a large, randomized phase III trial.

29 Sep 2025

Gene expression test identifies prostate cancer patients who benefit from hormone therapy

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the first predictive biomarker in this setting.

29 Sep 2025

Combining radiopharmaceuticals with targeted radiation improves progression-free survival in prostate cancer patients

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation, compared with radiation alone.

29 Sep 2025

UCLA presents advances in radiation therapy at ASTRO 2025

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, including studies on targeted radioactive therapy for recurrent prostate cancer, new approaches to stereotactic body radiation for prostate and head and neck cancers, advances in MRI- and 5DCT-guided imaging for more precise treatments, and innovations in patient-focused cancer education.

26 Sep 2025

New T cell therapy targets CTNNB1 cancer mutation with promising results in animal studies

Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers like lung and prostate cancer.

26 Sep 2025